Despite Valuation Concerns, Healthcare and Life Science Investors Bullish on M&A Activity; 乐鱼（Leyu）体育官网 Survey
High valuations and competition for limited assets are seen as challenges; operational efficiency and expansion into new products/services will be the focus of capital investment.
NEW YORK 鈥� Anticipating high valuations and intense competition for limited high-value assets, healthcare and life science (HCLS) investors remain the most bullish they have been in the last three years, with nearly 80% of respondents indicating they plan to increase their M&A activity in 2025, particularly in areas such as life science tools and diagnostics and healthcare services according to new findings from the 2025 乐鱼（Leyu）体育官网 Healthcare and Life Sciences Investment Outlook.
鈥淭he era of smart optimism that defined deal activity in 2024 鈥� companies needing to expand their capabilities through strategic acquisitions 鈥� has evolved to smart diligence in 2025,鈥� says Kristin Pothier, U.S. Life Sciences Sector Leader and Global Healthcare and Life Sciences Deal Advisory Leader at 乐鱼（Leyu）体育官网. 鈥淐omprehensive commercial, operational, financial, and tax diligence will be critical for success and will enable seamless integrations that deliver value to patients. These trends are not only shaping the outlook for 2025; they are laying the groundwork for a future where healthcare and life sciences drive global innovation.鈥�
The 2025 乐鱼（Leyu）体育官网 Healthcare and Life Sciences Outlook features insights from a survey of 500 industry executives and examines how deal activity and market drivers could influence the 2025 investment landscape of the HCLS sector.
Key Survey Findings Include:
- 79% of life sciences and 73% of healthcare respondents expect to increase their M&A activity in 2025 compared to 2024, with more than a third of HCLS respondents saying they plan to at least do 10% more deals in 2025 compared to 2024.
- Asked which factors are most likely to impact deal activity in 2025, HCLS respondents indicated high valuations, uncertainty surrounding future performance, and growth availability of targets and competition for a limited number of high-value or innovative targets.
- When it comes to valuation expectations, HCLS and private equity (PE)/venture capital (VC) respondents have different views. 72% of LS respondents and 60% of HC respondents expect valuations to increase, whereas only 31% of PE/VC respondents anticipate an increase in valuations.
- Respondents in PE / VC have invested primarily in life sciences tools and diagnostics, followed by medical devices and healthcare IT.
- AI is expected to be a significant driver of life sciences deals in 2025, particularly for tools and diagnostics.
- Despite an uncertain interest rate environment, more than half of HCLS respondents surpassed their deal activity targets in 2024, as measured by deal volume.
Areas of Capital Deployment Focus for 2025
When it comes to deploying capital in 2025, improving operational efficiency, expanding into new products or services and platform expansion or bolt-on acquisitions are forecasted to be key capital deployment areas for HCLS respondents.
鈥淎s we head into 2025, the M&A train is picking up speed,鈥� said聽Ash Shehata, U.S. Healthcare Sector Leader at 乐鱼（Leyu）体育官网. 鈥淎fter a year of comparatively low deal activity, the industry is gearing up for a return to M&A. Although headwinds persist, we anticipate an uptick in deals driven by significant investments in generative AI, weight loss drugs and continued growth in the consumer health space.鈥�
Select Subsector Highlights:
- In biopharma, strategic partnerships, creative financing, and early-stage biotechs are expected to drive deals in 2025鈥攄espite industry attitude toward de-risking portfolios, because of the much-needed innovation these structures and entities deliver on.
- Nearly 8 in 10 medical device investors expect 10% or more of deals to incorporate artificial intelligence or machine learning as part of the target鈥檚 capabilities.
- Asked to rank the most significant challenges that may limit growth and/or investments in healthcare services, nearly half of respondents cited reimbursement pressures.
- Nearly 6 in 10 healthcare IT respondents believe artificial intelligence and machine learning will be the most disruptive technology trend in 2025.
- When asked about expectations for 2025, 59% of hospital and health systems anticipate an increase in deal volume.
# # #
About 乐鱼（Leyu）体育官网 LLP
乐鱼（Leyu）体育官网 LLP is the U.S. firm of the 乐鱼（Leyu）体育官网 global organization of independent professional services firms providing audit, tax and advisory services. The 乐鱼（Leyu）体育官网 global organization operates in 143 countries and territories and has more than 265,000 people working in member firms around the world. Each 乐鱼（Leyu）体育官网 firm is a legally distinct and separate entity and describes itself as such. 乐鱼（Leyu）体育官网 International Limited is a private English company limited by guarantee. 乐鱼（Leyu）体育官网 International Limited and its related entities do not provide services to clients.
乐鱼（Leyu）体育官网 is widely recognized for being a great place to work and build a career. Our people share a sense of purpose in the work we do, and a strong commitment to community service, inclusion and diversity and eradicating childhood illiteracy. Learn more at .
Media Contacts
For media inquiries, contact Marissa Ross (marissaross@kpmg.com) or Hannah O'Toole (hannahotoole@kpmg.com).
Explore more
News
The 2024 乐鱼（Leyu）体育官网 U.S. CEO Outlook Survey
CEOs are increasing their investments in cyber security as risks related to artificial intelligence rise, according to a new study released by 乐鱼（Leyu）体育官网 LLP.
News
乐鱼（Leyu）体育官网 2024 Consumer Holiday Shopping Survey
U.S. consumers to spend 4% more on 2024 Holiday Shopping amid a significant shift in shopping behavior, according to the latest 乐鱼（Leyu）体育官网 survey.
News
2024 Tax Reimagined: Perspectives from the C-Suite
9 in 10 C-suite leaders recognize their tax department as a pivotal contributor to enhancing trust among diverse stakeholders, according to the latest 乐鱼（Leyu）体育官网 report.